World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
80
Citations
21405
World Ranking
1642
National Ranking
65

Ferry Ossendorp publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ferry Ossendorp sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 246 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Ferry Ossendorp D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ferry Ossendorp sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Ferry Ossendorp is affiliated with Leiden University Medical Center in the Netherlands, contributing extensively to research in immunology and medicine. Their work predominantly focuses on fields such as Immunology and Microbiology, with significant involvement in subfields including Immunology, Oncology, Molecular Biology, Biomedical Engineering, and Pulmonary and Respiratory Medicine.

The research topics covered by Ossendorp span a diverse array of subjects related to immune system function and cancer treatment. Key areas include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Nanoplatforms for cancer theranostics, CAR-T cell therapy research, vaccines and immunoinformatics approaches, Immune Cell Function and Interaction, and Photodynamic Therapy Research Studies.

Ossendorp's recent publications demonstrate a focus on cancer immunotherapy and drug delivery systems. Notable papers include:

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy, 2020, Science Translational Medicine
  • Liposome-Based Drug Delivery Systems in Cancer Immunotherapy, 2020, Pharmaceutics
  • Current Challenges and Opportunities of Photodynamic Therapy against Cancer, 2023, Pharmaceutics
  • Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations, 2020, Journal of Clinical Medicine
  • Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies, 2020, Journal of Controlled Release

Frequent collaborators in their research include Marcel Camps, Luis J. Cruz, Ramon Arens, Martine J. Jager, and Sen Ma. These coauthors have contributed to multiple projects, reflecting ongoing scientific partnerships.

Ossendorp's work appears regularly in prominent journals and publication venues such as Pharmaceutics, Journal of Controlled Release, Investigative Ophthalmology & Visual Science, ChemBioChem, and Methods in Molecular Biology. These venues illustrate the interdisciplinary nature of their research spanning immunology, drug delivery, and molecular science.

Best Publications

  • Therapeutic cancer vaccines

    Cornelis J.M. Melief;Thorbald van Hall;Ramon Arens;Ferry Ossendorp

  • Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

    Ferry Ossendorp;Erica Mengedé;Marcel Camps;Rian Filius

  • Vaccines for established cancer: overcoming the challenges posed by immune evasion.

    Sjoerd H. van der Burg;Ramon Arens;Ferry Ossendorp;Thorbald van Hall

  • Decreased tumor surveillance in perforin-deficient mice.

    M. F. Van Den Broek;D. Kagi;F. Ossendorp;R. Toes

  • CD4 T cells and their role in antitumor immune responses.

    René E.M. Toes;Ferry Ossendorp;Rienk Offringa;Cornelis J.M. Melief

  • Proteasome and peptidase function in MHC-class-I-mediated antigen presentation.

    Peter Michael Kloetzel;Ferry Ossendorp

  • CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope

    Ania Skowera;Richard J. Ellis;Ruben Varela-Calviño;Sefina Arif

  • MHC II In dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways

    Sonja I. Buschow;Esther N. M. Nolte‐‘t Hoen;Guillaume Van Niel;Maaike S. Pols

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

    Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  • Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

    Marieke F. Fransen;Mark Schoonderwoerd;Philipp Knopf;Marcel G.M. Camps

  • Efficient Identification of Novel HLA-A * 0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis

    Jan H. Kessler;Nico J. Beekman;Sandra A. Bres-Vloemans;Pauline Verdijk

  • Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells

    Monique Kleijmeer;Georg Ramm;Danita Schuurhuis;Janice Griffith

  • Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes

    Gabrielle G. M. Pinkse;Odette H. M. Tysma;Cees A. M. Bergen;Michel G. D. Kester

  • Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo

    Danita H. Schuurhuis;Andreea Ioan-Facsinay;Bas Nagelkerken;Jolien J. van Schip

  • Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.

    Jan Paul Medema;Danita H. Schuurhuis;Delphine Rea;Joost van Tongeren

  • CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

    Rodney A. Rosalia;Luis J. Cruz;Suzanne van Duikeren;Angelino T. Tromp

  • Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell–Independent or–Dependent Stimuli

    Danita H. Schuurhuis;Sandra Laban;René E.M. Toes;Paola Ricciardi-Castagnoli

  • PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.

    A. L. Silva;P. C. Soema;B. Slütter;F. Ossendorp

  • Strategies for immunotherapy of cancer

    C J Melief;R E Toes;J P Medema;S H van der Burg

  • Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

    Rodney A. Rosalia;Esther D. Quakkelaar;Anke Redeker;Selina Khan

  • Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination.

    Guillaume van Niel;Richard Wubbolts;Toine ten Broeke;Sonja I. Buschow

Frequent Co-Authors

Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Thorbald van Hall
Thorbald van Hall Leiden University Medical Center
Sjoerd H. van der Burg
Sjoerd H. van der Burg Leiden University Medical Center
Ramon Arens
Ramon Arens Leiden University Medical Center
Rienk Offringa
Rienk Offringa German Cancer Research Center
Herman S. Overkleeft
Herman S. Overkleeft Leiden University
René E. M. Toes
René E. M. Toes Leiden University Medical Center
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Wim Jiskoot
Wim Jiskoot Leiden University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, expanding your qualifications can open diverse career opportunities. Many students transition into healthcare roles through specialized nursing degrees, which complement immunology knowledge and enhance patient care skills.

If you’re considering a fast-track route, exploring accelerated nurse practitioner programs can offer an efficient pathway to advanced clinical roles. These programs build on your science background, preparing you for leadership in immunology-related healthcare settings.

Alternatively, non-nurses interested in the healthcare field can benefit from online nursing programs for non nurses. These programs provide foundational nursing education accessible to those without a prior nursing background, facilitating a smoother transition into healthcare careers.

For those seeking easier admission options, identifying the easiest accelerated nursing programs or accredited lpn programs easy to get into could be the key. These options help expedite entry into the nursing workforce while maintaining quality education standards.

Integrating immunology with nursing credentials can broaden your impact in healthcare, research, and patient education, making these pathways highly valuable for your career development.

Best Scientists Citing Ferry Ossendorp

Trending Scientists

Recently Published Articles